Biosimilars in 2023 Early Observations of Adalimumab and Expectations for

Source

This webinar will be of interest to biosimilar innovators, especially, but the broader industry will benefit from an in-depth analysis of biosimilar uptake drivers and early performance evidence.

Key objectives:

  • Understand current market forces and influence on biosimilars today
  • Evaluate adalimumab biosimilar uptake and various launch approaches
  • Identify areas to watch and explore, including the potential impact of the Inflation Reduction Act and other industry disruptions on the future state of biosimilars

Speakers

Eric Foster
Managing Principal, U.S. Market Access Strategy Consulting, IQVIA

Teddy Landsman
Principal, U.S. Market Access Strategy Consulting, IQVIA